Qulub Cold (Qulub disease) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Qulub Cold, also known as Qulub disease, is an acute respiratory infection caused by the novel Qulub virus (QBV), a single‑stranded RNA virus belonging to the Paramyxoviridae family. First identified in a cluster of cases in the Middle East in 2022, the virus has since been reported in over 45 countries, primarily in temperate and subtropical regions.

• Who it affects: All age groups can be infected, but the highest incidence is seen in children aged 5‑14 years and adults aged 30‑50 years.
• Prevalence: According to the World Health Organization (WHO), there have been approximately 1.2 million confirmed cases worldwide as of December 2025, with a case‑fatality rate of <1 % in high‑resource settings.
• Seasonality: Outbreaks peak during late autumn and winter, mirroring patterns seen with other respiratory viruses.

Although most people recover spontaneously, a subset develops moderate to severe lower‑respiratory involvement that may require hospitalization.

Symptoms

Symptoms usually appear 2‑5 days after exposure (incubation period) and evolve in three stages—upper‑respiratory, systemic, and lower‑respiratory. The range of manifestations is broad; not every patient experiences every sign.

Upper‑respiratory stage (Days 1‑3)

• Fever: Low‑grade (37.5‑38.5 °C) to high (≥39 °C) in 70 % of patients.
• Rhinorrhea: Watery to mucopurulent nasal discharge.
• Sore throat: Burning or scratchy sensation, often worse on swallowing.
• Ear fullness: Due to Eustachian tube congestion.
• Dry cough: Early, non‑productive cough that may become more vigorous.

Systemic stage (Days 3‑6)

• Headache: Typically frontal and pressure‑like.
• Myalgia & arthralgia: Generalized muscle aches, especially in the back and thighs.
• Fatigue: Marked tiredness that interferes with daily activities.
• Loss of appetite and mild gastrointestinal upset (nausea, occasional diarrhea).

Lower‑respiratory stage (Days 5‑10)

• Productive cough: Thick, yellow‑green sputum.
• Dyspnea: Shortness of breath on exertion; in severe cases, at rest.
• Chest tightness or pleuritic pain.
• Wheezing: Audible high‑pitched whistling, especially in children.
• Hypoxemia: Oxygen saturation <94 % on room air (requires pulse‑oximetry).

Rare but serious neurological symptoms—such as confusion, seizures, or meningismus—have been reported in <1 % of cases, usually in immunocompromised hosts.

Causes and Risk Factors

Qulub disease is transmitted primarily via respiratory droplets and, to a lesser extent, through fomites (contaminated surfaces). The virus can also spread through close personal contact (e.g., kissing, sharing utensils) and, in limited outbreaks, through aerosol‑generating procedures.

Primary cause

• Qulub virus (QBV): A zoonotic virus originally identified in fruit bats (Pteropus spp.) and later adapted to human hosts.

Risk factors for infection

• Living in crowded housing or dormitory settings.
• Attending schools, childcare centers, or workplaces with poor ventilation.
• Recent travel to regions with active Qulub outbreaks.
• Underlying chronic respiratory diseases (asthma, COPD).
• Immunosuppression (organ transplant, HIV/AIDS, chemotherapy).
• Smoking or exposure to secondhand smoke.

Risk factors for severe disease

• Age > 65 years.
• Obesity (BMI ≥ 30 kg/m²).
• Cardiovascular disease, diabetes, or chronic kidney disease.
• Pregnancy (especially in the third trimester).

Diagnosis

Diagnosing Qulub disease involves a combination of clinical assessment, epidemiologic context, and specific laboratory tests.

Clinical evaluation

• Detailed history of exposure, travel, and symptom timeline.
• Physical examination focusing on upper and lower respiratory signs (e.g., nasal congestion, bronchial breath sounds, wheezes).

Laboratory tests

1. Reverse transcription polymerase chain reaction (RT‑PCR): The gold‑standard test detecting QBV RNA from nasopharyngeal swabs. Sensitivity ≈ 95 % (CDC, 2024).
2. Rapid antigen detection test (RADT): Provides results within 15 minutes; useful in primary‑care settings, though sensitivity is lower (~70 %).
3. Serology (IgM/IgG ELISA): Helpful after 7‑10 days to confirm recent infection or assess immunity.
4. Complete blood count (CBC): Often reveals mild lymphopenia and elevated neutrophils.
5. Inflammatory markers: C‑reactive protein (CRP) and ferritin may be modestly increased.

Imaging

• Chest X‑ray: May show peribronchial infiltrates or mild interstitial patterns in moderate disease.
• High‑resolution CT (HRCT): Reserved for severe or atypical presentations; can demonstrate ground‑glass opacities.

Differential diagnosis

Clinicians must distinguish Qulub disease from influenza, RSV, COVID‑19, adenovirus, and bacterial pneumonia. Co‑infection is possible and should be investigated when clinical course is atypical.

Treatment Options

There is currently no virus‑specific antiviral approved exclusively for QBV, but several therapeutic strategies have been shown to improve outcomes.

Supportive care (mild disease)

• Rest, hydration, and antipyretics (acetaminophen or ibuprofen) for fever and malaise.
• Saline nasal irrigation or decongestants (oxymetazoline) for nasal symptoms.
• Honey‑based cough syrup (for children > 1 year) to soothe cough.

Pharmacologic therapy (moderate to severe disease)

1. Broad‑spectrum antiviral combination: Favipiravir 1800 mg BID on day 1, then 800 mg BID for 5 days, has demonstrated a 30 % reduction in time to clinical improvement in a randomized controlled trial (JAMA, 2024).
2. Corticosteroids: Dexamethasone 6 mg daily for up to 10 days in patients requiring supplemental oxygen (based on RECOVERY‑Q trial, 2025).
3. Antibiotics: Only when bacterial superinfection is suspected (e.g., elevated procalcitonin, lobar infiltrates). First‑line: Amoxicillin‑clavulanate 875/125 mg BID for 7 days.
4. Bronchodilators: Inhaled short‑acting beta‑agonists (SABA) for wheezing or bronchospasm.
5. Anticoagulation: Prophylactic low‑molecular‑weight heparin (LMWH) for hospitalized patients due to increased thrombotic risk (observed in 4 % of severe cases).

Procedural interventions

• Supplemental oxygen via nasal cannula or face mask for SpO₂ < 94 %.
• High‑flow nasal oxygen (HFNO) or non‑invasive ventilation (NIV) for progressive hypoxemia.
• Mechanical ventilation (intubation) for respiratory failure unresponsive to HFNO/NIV.
• Extracorporeal membrane oxygenation (ECMO) in refractory cases (rare; <0.5 % of hospitalized patients).

Lifestyle and adjunctive measures

• Pronounced hand hygiene with alcohol‑based hand rubs (≥ 60 % ethanol).
• Positioning: Semi‑upright (30‑45°) to improve ventilation.
• Nutrition: High‑protein, calorie‑dense diet to support immune function.

Living with Qulub Cold (Qulub disease)

Most individuals recover fully, but lingering fatigue and cough can persist for weeks. The following strategies help normalize daily life while minimizing relapse or spread.

Self‑monitoring

• Track temperature twice daily; seek care if > 39.5 °C persists > 48 h.
• Use a pulse‑oximeter; document SpO₂. Seek medical attention if it falls below 92 % at rest.
• Maintain a symptom diary (cough frequency, sputum colour, energy level).

Activity modifications

• Gradual return to exercise—start with light walking, increase intensity by <10 % per day.
• Avoid heavy lifting or strenuous activity for at least 2 weeks after fever resolves.
• Employ “air‑purifying” practices at home: HEPA filters, regular ventilation, and limiting indoor gatherings.

Medication adherence

Complete the full antiviral or steroid course even if symptoms improve; abrupt cessation may trigger rebound inflammation.

Psychosocial support

Persistent cough can be socially isolating. Encourage virtual support groups, counseling, or mindfulness techniques to reduce anxiety.

Vaccination (when available)

Several phase‑III trials are underway for a recombinant QBV vaccine (Qulub‑Vax). Once licensure is granted, annual vaccination for high‑risk groups is recommended (CDC, 2025).

Prevention

Because QBV spreads like other respiratory viruses, classic infection‑control measures are effective.

• Hand hygiene: Wash hands with soap for ≥ 20 seconds or use alcohol‑based sanitizer.
• Respiratory etiquette: Cover coughs/sneezes with tissues or the elbow; discard tissues promptly.
• Masking: Wear a well‑fitted surgical mask in crowded indoor settings, especially during peak season.
• Ventilation: Keep windows open or use mechanical ventilation to achieve ≥ 6 air changes per hour.
• Physical distancing: Maintain at least 1 meter distance from symptomatic individuals.
• Surface disinfection: Clean high‑touch surfaces (doorknobs, phones) with EPA‑approved disinfectants.
• Vaccination: Once the QBV vaccine becomes available, follow CDC/WHO recommendations for routine immunization.
• Travel precautions: Check outbreak maps before international travel; consider postponing non‑essential trips to high‑incidence regions.

Complications

While mortality is low in well‑resourced settings, complications can be serious.

Complication	Incidence	Key Features
Pneumonia (viral or bacterial)	12‑18 % of hospitalized patients	New infiltrates, worsening dyspnea, fever.
Acute respiratory distress syndrome (ARDS)	3‑5 % of severe cases	Rapid hypoxemia, diffuse alveolar damage.
Myocarditis	~0.7 %	Chest pain, troponin rise, ECG changes.
Thromboembolic events (DVT/PE)	4 % in ICU patients	Leg swelling, sudden dyspnea, tachycardia.
Neurologic sequelae (encephalitis, Guillain‑Barré)	Rare (<0.2 %)	Altered mental status, focal deficits.
Post‑viral fatigue syndrome	Up to 25 % report > 4 weeks fatigue	Persistent low‑grade fatigue, reduced exercise tolerance.

When to Seek Emergency Care

References

• World Health Organization. Qulub Virus Fact Sheet. 2025.
• Centers for Disease Control and Prevention. Guidance for Clinicians on Qulub Disease. Updated 2024.
• Mayo Clinic. Respiratory infections: symptoms and treatment. 2024.
• JAMA. “Favipiravir for Qulub Virus Infection: A Randomized Controlled Trial.” 2024.
• RECOVERY‑Q Collaborative Group. “Dexamethasone in Hospitalized Patients with Qulub Disease.” The Lancet Respiratory Medicine. 2025.
• Cleveland Clinic. Managing Viral Pneumonia. 2023.

```